Kintara Therapeutics, NASDAQ: KTRA Revenue

Biotechnology Research • San Diego, California, United States • 1-10 Employees

Kintara Therapeutics, NASDAQ: KTRA revenue & valuation

Annual revenue	$427,775
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,400,000
Total funding	No funding

Key Contact at Kintara Therapeutics, NASDAQ: KTRA

Saiid Zarrabian

Head of Strategic Partnerships & Member of the Board of Directors

Company overview

Headquarters	12707 High Bluff Dr, Suite 200, San Diego, California 92130, US
Phone number	+18583504364
Websites	kintara.com delmarpharma.com
NAICS	541714
SIC	283
Keywords	Cancer, Ovarian Cancer, GBM, Glioblastoma Multiforme, Cutaneous Metastatic Breast Cancer, Pediatric Cns Tumors, Recurrent Basal Cell Carcinoma Nevus Syndrome, Hemodialysis Arteriovenous (Av) Access
Employees	1-10
Socials

About Kintara Therapeutics, NASDAQ: KTRA

Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. A Pipeline of Breakthrough Cancer Therapeutics VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083's indications include: Glioblastoma Multiforme (GBM) Ovarian Cancer Pediatric CNS Tumors REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds. REM-001’s indications include: Cutaneous Metastatic Breast Cancer Recurrent Basal Cell Carcinoma Nevus Syndrome Hemodialysis Arteriovenous (AV) Access

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Partner

Funding Data

Kintara Therapeutics, NASDAQ: KTRA has never raised funding before.

Kintara Therapeutics, NASDAQ: KTRA Tech Stack

Discover the technologies and tools that power Kintara Therapeutics, NASDAQ: KTRA's digital infrastructure, from frameworks to analytics platforms.

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

Klaro

Cookie compliance

Preact

JavaScript libraries

HSTS

Security

FancyBox

JavaScript libraries

Open Graph

Miscellaneous

core-js

JavaScript libraries

Bootstrap

UI frameworks

Google Analytics

Analytics

RSS

Miscellaneous

hCaptcha

Security

Frequently asked questions

Kintara Therapeutics, NASDAQ: KTRA is located in San Diego, California, US.

You can reach Kintara Therapeutics, NASDAQ: KTRA at +18583504364.

Kintara Therapeutics, NASDAQ: KTRA generates an estimated annual revenue of $427,775. This revenue figure reflects the company's market position and business performance in its industry.

Kintara Therapeutics, NASDAQ: KTRA has an estimated valuation of $1,400,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Kintara Therapeutics, NASDAQ: KTRA has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Kintara Therapeutics, NASDAQ: KTRA

Saiid Zarrabian

Head of Strategic Partnerships & Member of the Board of Directors

4.8

40,000 users